|Bid||0.8200 x 800|
|Ask||0.8750 x 3000|
|Day's Range||0.8000 - 0.8900|
|52 Week Range||0.6300 - 8.4000|
|Beta (5Y Monthly)||1.84|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.00|
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
The Company has made plans for a smooth transition. Mr. Weinstein is a finance and accounting senior executive with over 30 years of “hands-on” public and private company management, investment banking and private equity investing experience.
January is turning out to be a bit of a roller-coaster market for my main account. The last trade I took in the account on Wednesday in Neurotrope, Inc. (NASDAQ: NTRP) ended up netting me another $166 in the account.
Neurotrope, Inc. (the "Company") (NASDAQ:NTRP) today announced that it has received commitments from institutional investors and pre-existing high net worth individuals to purchase an aggregate of $18 million of the Company's securities in a registered direct offering.
Neurotrope, Inc. (Nasdaq: NTRP) ("Neurotrope" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, today announced its corporate update.
NEW YORK, Oct. 8, 2019 /PRNewswire/ -- Neurotrope, Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, today announced its plans to explore strategic alternatives to maximize shareholder value. "Following the results from our Phase 2 study of Bryostatin-1 in Alzheimer's disease, we believe a review of strategic alternatives is an important step toward preserving and enhancing shareholder value," stated Dr. Charles S. Ryan, Neurotrope's Chief Executive Officer. There can be no assurance that the formal strategic review of alternatives will result in any successful transaction or other outcome.
Boston Scientific (BSX) is hopeful about robust data outcome on DAPT study as the therapy duration might prove to be a superior treatment option.
Align Technology (ALGN) succeeds in consecutively delivering a solid spurt in Invisalign Technology volumes across the company's entire clientele.
This latest FDA approval of Medtronic's (MDT) Evolut PRO+ follows the last month's nod from the regulatory body for the Evolut TAVR system with regard to expanded indication.
With this reimbursement approval, Abbott's (ABT) FreeStyle Libre becomes the first sensor-based glucose monitoring system to be listed by any provincial health plan in Canada.
Walgreens' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also gaining traction from a solid retail prescription market.